The European Union is pleased to announce that the Department of Biotechnology, Government of India, joins the international initiative to tackle Antimicrobial Resistance
Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
On 29 June 2017, India, South Africa and Egypt were accepted as new members of the European Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). This global forum aiming at curbing the resistance to antibiotics counts now 26 member countries of which 20 from Europe and 6 from outside Europe: Argentina, Canada, Egypt, Japan, India and South Africa.
Congratulations to the Department of Biotechnology (DBT) of India for becoming member of JPIAMR: it means that India’s “National Action Plan on Antimicrobial Resistance” was considered well established and includes serious efforts on research and innovation all contributing to improve the capacity on Antimicrobial Resistance (AMR) in the coming years. Through this Platform, increased opportunities on international R&I collaboration on AMR will be offered, which in turn will help further strengthening India’s R&I capacity on AMR.
What is a Joint Programming Initiative (JPI)?
JPI is an initiative launched by the European Union aiming at addressing a given problem through cross-border cooperation of research funding. The issues to be addressed are of such a nature that a single Member State cannot address it alone. Concentration of efforts is required as well as alignment of national programmes. In doing so, a critical mass is being created and duplication of research funding is avoided.
JPIs have their own governance structures; the member countries are on geometry variable basis depending on interest in a given field and R&I capacity. The JPI member countries establish a joint Strategic Research Agenda together. Currently 11 Joint Programming Initiatives (JPIs) have been launched (notably on Food Security, Agriculture & Climate Change; Cultural Heritage & Global Change; Urban Europe; Water Challenges for a Changing World).
The EU is offering financial support to these initiatives through the EU Research and Innovation Framework Programme ‘Horizon 2020’ (2014-2020).
Why a JPI on AMR?
Antibacterial resistance is a multifaceted problem needing vast and versatile solutions. No individual sector or nation has the capacity to independently handle this major societal challenge. Therefore, to collectively address antibacterial resistance at a national level and to increase the current impact of public research through more effective, efficient, and aligned investment, the JPIAMR was established in 2011 and by June 2017 it brings together 26 member countries. The secretariat is hosted by the Swedish Research Council in Stockholm, Sweden.
The JPIAMR launched its strategic research agenda in April, 2014, outlining the member states’ common vision to tackle antibacterial resistance. The strategic research agenda identifies six priority topics (therapeutics, diagnostics, surveillance, transmission, environment, and interventions). The JPIAMR has also organised joint calls for proposals on AMR as well as information sharing among the Members on AMR and convening of various experts’ meetings.
The collaborative platform is by now internationally recognized: JPIAMR interacts with stakeholders such as the World Health Organisation (WHO), the ASEAN countries, G7 and the G20. The JPIAMR coordinates research priorities and calls with the EC and pharmaceutical industry. At the G7 in Elmau (Germany) in 2015, the health ministers agreed on joint efforts to combat AMR and in 2016, AMR was treated as one of the top priorities for global health at the G7 at the Ise-Shima Summit.
The Future – Global Collaboration Creates Transformative Changes
The mission for JPIAMR for the years 2020-2025 is stated as: “To join forces across nations by leading the alignment, coordination, and support to Antimicrobial Resistance One Health collaborative research and global policy activities”.
JPI AMR and India
India recognizes the importance of strengthening global capacity to counter infectious disease threats and is working across sectors to address antimicrobial resistance (AMR).
DBT will participate in the next board meeting of the JPIAMR to be held on 10-11 October 2017 in Stockholm (Sweden) where DBT will give the overview of its activities and funding for research on AMR. It is expected that DBT will further contribute to this initiative, through various activities, such as participating in joint calls and joint mapping efforts for the coming year